中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2012年
4期
257-260
,共4页
程志祥%邹善华%李锋%李军民%王健民%陈芳源%曹军宁%王椿%魏征%程韵枫
程誌祥%鄒善華%李鋒%李軍民%王健民%陳芳源%曹軍寧%王椿%魏徵%程韻楓
정지상%추선화%리봉%리군민%왕건민%진방원%조군저%왕춘%위정%정운풍
淋巴瘤,弥漫大B细胞%抗肿瘤联合化疗方案%抗体,单克隆,CD20%多中心研究%回顾性研究
淋巴瘤,瀰漫大B細胞%抗腫瘤聯閤化療方案%抗體,單剋隆,CD20%多中心研究%迴顧性研究
림파류,미만대B세포%항종류연합화료방안%항체,단극륭,CD20%다중심연구%회고성연구
Lymphoma,diffuse large B cell%Antineoplastic combined chemotherapy protocols%Monoclonal antibody,CD20%Multicenter studies%Retrospective studies
目的 观察R-CHOP方案对初治弥漫大B细胞淋巴瘤(DLBCL)患者的有效性、安全性及长期预后的影响,并与CHOP方案作比较.方法 2000年1月1日至2010年5月1日507例初发DLBCL患者进入本研究,分为CHOP及R-CHOP两组.CHOP组接受6个疗程CHOP方案,R-CHOP组患者接受至少4个疗程R-CHOP方案化疗,之后两个疗程采用R-CHOP方案或CHOP方案治疗.利妥昔单抗剂量为375 mg/m2,CHOP方案:环磷酰胺750 mg/m2、阿霉素50 mg/m2、长春新碱1.4 mg/m2(最大剂量2.0 mg/m2)、泼尼松60～100 mg.结果 411例可分析病例中,CHOP组224例,其中完全反应(CR)160例(71.43%),总有效率(ORR)为87.95%;R-CHOP组187例,其中CR 144例(77.01%),ORR为95.19%.R-CHOP组较CHOP组的ORR显著提高(P=0.007).CHOP组中位随访时间35.2个月,R-CHOP组中位随访时间28.1个月,随访至终点时,CHOP组预期中位无进展生存(PFS)时间84.8个月,R-CHOP组尚未达到中位PFS,两组均未达到中位总生存(OS)时问.采用Kaplan-Meier法进行生存分析,两组患者的PFS及OS间差异有统计学意义(P值均<0.05).R-CHOP组不良反应与CHOP组类似.结论 利妥昔单抗联合CHOP方案可有效用于初治DLBCL,具有更高的缓解率,延长PFS时间和提高OS率,同时未明显增加不良反应.
目的 觀察R-CHOP方案對初治瀰漫大B細胞淋巴瘤(DLBCL)患者的有效性、安全性及長期預後的影響,併與CHOP方案作比較.方法 2000年1月1日至2010年5月1日507例初髮DLBCL患者進入本研究,分為CHOP及R-CHOP兩組.CHOP組接受6箇療程CHOP方案,R-CHOP組患者接受至少4箇療程R-CHOP方案化療,之後兩箇療程採用R-CHOP方案或CHOP方案治療.利妥昔單抗劑量為375 mg/m2,CHOP方案:環燐酰胺750 mg/m2、阿黴素50 mg/m2、長春新堿1.4 mg/m2(最大劑量2.0 mg/m2)、潑尼鬆60～100 mg.結果 411例可分析病例中,CHOP組224例,其中完全反應(CR)160例(71.43%),總有效率(ORR)為87.95%;R-CHOP組187例,其中CR 144例(77.01%),ORR為95.19%.R-CHOP組較CHOP組的ORR顯著提高(P=0.007).CHOP組中位隨訪時間35.2箇月,R-CHOP組中位隨訪時間28.1箇月,隨訪至終點時,CHOP組預期中位無進展生存(PFS)時間84.8箇月,R-CHOP組尚未達到中位PFS,兩組均未達到中位總生存(OS)時問.採用Kaplan-Meier法進行生存分析,兩組患者的PFS及OS間差異有統計學意義(P值均<0.05).R-CHOP組不良反應與CHOP組類似.結論 利妥昔單抗聯閤CHOP方案可有效用于初治DLBCL,具有更高的緩解率,延長PFS時間和提高OS率,同時未明顯增加不良反應.
목적 관찰R-CHOP방안대초치미만대B세포림파류(DLBCL)환자적유효성、안전성급장기예후적영향,병여CHOP방안작비교.방법 2000년1월1일지2010년5월1일507례초발DLBCL환자진입본연구,분위CHOP급R-CHOP량조.CHOP조접수6개료정CHOP방안,R-CHOP조환자접수지소4개료정R-CHOP방안화료,지후량개료정채용R-CHOP방안혹CHOP방안치료.리타석단항제량위375 mg/m2,CHOP방안:배린선알750 mg/m2、아매소50 mg/m2、장춘신감1.4 mg/m2(최대제량2.0 mg/m2)、발니송60～100 mg.결과 411례가분석병례중,CHOP조224례,기중완전반응(CR)160례(71.43%),총유효솔(ORR)위87.95%;R-CHOP조187례,기중CR 144례(77.01%),ORR위95.19%.R-CHOP조교CHOP조적ORR현저제고(P=0.007).CHOP조중위수방시간35.2개월,R-CHOP조중위수방시간28.1개월,수방지종점시,CHOP조예기중위무진전생존(PFS)시간84.8개월,R-CHOP조상미체도중위PFS,량조균미체도중위총생존(OS)시문.채용Kaplan-Meier법진행생존분석,량조환자적PFS급OS간차이유통계학의의(P치균<0.05).R-CHOP조불량반응여CHOP조유사.결론 리타석단항연합CHOP방안가유효용우초치DLBCL,구유경고적완해솔,연장PFS시간화제고OS솔,동시미명현증가불량반응.
Objective To evaluate the efficacy,safety and prognostic impact of rutiximab plus CHOP(R-CHOP)regimen on patients with diffuse large B-cell lymphoma(DLBCL),to access the impact of R-CHOP on patients'prognosis and to compare that with CHOP regimen.Methods Five hundred and seven newly diagnosed DLBCL patients were enrolled from Jan.1,2000 to May 1,2010.Patients were adminis-tered with 6 cycles of CHOP or at least 4 cycles of R-CHOP treatments.Rutiximab was administered intrave-nously on dayl at a dose of 375 mg/m2.The typical CHOP regimen include cyclophosphamide(750 mg/m2,1V),doxombicin(50 mg/m2,IV)and vincristine(1.4 mg/m2,IV,maximum 2 mg)and prednisone (60-100 mg,oral,day 3-7).The complete response(CR)rates,overall response(OR)rates,and side events of these 2 groups were compared.Results Of the 41 1 analyzable patients,224 received CHOP regi-men and 187 received R-CHOP regimen.CR rate for R-CHOP group and CHOP group was 77.01%and 71.43%,respectively.OR rate in R-CHOP group was higher than that in the CHOP group(95.19%VS 87.95%,P=0.007).The median follow-up time of R-CHOP group was 28.1 months vs that of35.2 months in CHOP group.There was significant difference in progression free survival(PFS)and overall survival (OS) between 2 groups ( P =0.018 and 0. 034, respectively). At the end of follow-up, the estimated median PFS in R-CHOP group had not been reached, while that was 84. 8 months in CHOP group. The median OS in both groups had not yet been reached. The adverse events in R-CHOP group were similar with that in CHOP group. Conclusions R-CHOP is a safe and effective regimen for management of newly diagnosed DLBCL, with a better remission rate, PFS and OS.
